Bukwang Pharmaceutical Launches New Liver Disease Treatment "Regadex"

Exterior view of Bukwang Pharmaceutical headquarters. Photo by Bukwang Pharmaceutical

Bukwang Pharmaceutical announced on June 2 that it has launched a new liver disease treatment product, "Regadex" (active ingredients: ursodeoxycholic acid + biphenyl dimethyl dicarboxylate).

Regadex is Bukwang Pharmaceutical's first combination drug, released as part of the expansion of the Regaron lineup for liver disease treatments. The active ingredients in Regadex are ursodeoxycholic acid (UDCA) and biphenyl dimethyl dicarboxylate (DDB).

UDCA has anti-inflammatory and antioxidant effects and works by rapidly normalizing AST (aspartate aminotransferase) levels. DDB is notable for its strength in quickly reducing ALT (alanine aminotransferase) levels. AST and ALT, which are commonly used as indicators of liver health, are related to inflammation. When liver cells are damaged due to inflammation, these enzymes are released into the bloodstream, resulting in elevated blood levels of AST and ALT.

A Bukwang Pharmaceutical representative explained, "According to Regadex clinical data, ALT levels normalize within four weeks and remain significantly improved for up to 24 weeks."

Bukwang Pharmaceutical has established a foundation in the liver disease treatment market with "Regaron" (active ingredient: silymarin). The company plans to carry out active marketing with the launch of this new product.

A Bukwang Pharmaceutical representative stated, "Based on 'Regaron,' which is already frequently prescribed for chronic liver disease patients, we have established a wide network in the domestic liver disease sector." The representative added, "We plan to position Regadex as the optimal reimbursable combination for co-prescription with Regaron, offering ingredients proven to improve liver disease, and will proceed with marketing accordingly."

Meanwhile, to commemorate the launch of Regadex, Bukwang Pharmaceutical held a "Regadex Presentation Contest" for its medical representatives (MRs) on May 23. During this event, two individuals were selected as "Regadex Detail (Pharmaceutical Explanation) Masters." These selected individuals will be responsible for training employees on Regadex and will continue to actively engage in sales activities in the field.

This content was produced with the assistance of AI translation services.